healthcare

In this interview, KKR's Richard Schoenfeld outlines where he is seeing stress in the market today.

Morningstar has released its Q4 2023 guide to undervalued stocks and there’s a few big hitters in the mix.

Miracle weight loss drugs are providing opportunity in the Healthcare sector, and its not Novo-Nordisk

Having taken a defensive view to date, the investment bank is now pulling in more risk and argues we’re in an expansionary phase.

Quality is one of the key factors for blue chip company status, but our definitions change. Here's what to look for in future blue chips.

It's not at the stage to charge up the defibrillator, but private health insurance stocks are facing some challenges

It’s no secret that small caps have struggled in recent times, but the coming environment could suit them.

If you want to find less crowded opportunities in structural change, Westpac Private Bank's George Toubia says you'll need to dig deeper.

Platinum's Dr Bianca Ogden shares the big tech trends transforming healthcare and companies she likes

Franklin Templeton's Francyne Mu discusses the biggest investment opportunities of today and the future in this edition of Rapid Fire.

In this episode, our guests name two growing healthcare stocks (and share their top tips for assessing the next generation of winners).

In this episode, Wilson Asset Management's Tobias Yao and Tyndall Asset Management's Tim Johnston analyse five small-cap healthcare stocks.

IPOs are down in volume but there are still some interesting prospects, according to this accounting firm's mid-year report.

Mark Arnold shares some stocks that bolstered his team's small-cap growth strategy last financial year and some other consistent performers.

Should investors nibble on a defensive market darling thats tumbled almost 10% in two days?

As Warren Buffett said in an interview in 1999, “the inescapable fact is that the value of an asset, whatever its character, cannot over the long term grow faster than...

The best opportunities are found when you don't follow the herd.

Eleanor Swanson may have picked funds management over a medical degree, but healthcare still has a place in her top picks.

Nanosonics has lived in the shadow of giants like Cochlear for years. Can several near-term growth levers propel the company to new heights?

One of Australia's premier mid-caps has handed down its first-half results. But has it managed to surprise the market yet again?